A Good Week For Cardiovascular Research Centers
This article was originally published in RPM Report
Executive Summary
FDA took regulatory actions related to cardiovascular outcomes trials in obesity, opioid-induced constipation, triglycerides and testosterone. But the number of new studies conducted may actually be smaller than it sounds.
You may also be interested in...
The Next Estrogen Or An Off-Label Star: Can FDA Turn Back The Clock On Testosterone?
Testosterone replacement products took a hit after an FDA advisory committee, but even if the agency follows their advice, panelists worried a label change will not curb use in the now infamous “Low-T” population; meanwhile, a vigorous pipeline of new testosterone formulations may be left in limbo.
At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE
If cardiovascular studies are required for non-cardiac drugs, they should be focused on specific signals of heart-related concern that may not include ischemic events, advisory committee cardiologists say during review of Novo Nordisk’s Saxenda for obesity.
Lilly Prices Trulicity Near Victoza, But Well Above Tanzeum
Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.